Extended Data Fig. 1: Novel MEN1 mutations detected in patients upon relapse on revumenib.
From: MEN1 mutations mediate clinical resistance to menin inhibition
a—c) Tables showing the results of the IMPACT targeted DNA-sequencing panel from patient 1–4 at the time point of screening prior to enrolling on the AUGMENT-101 trial and at relapse on revumenib treatment. MEN1 mutations are highlighted in red. d) Pie charts displaying the fraction of MEN1-mutant alleles measured by droplet digital PCR (ddPCR) at the time point of relapse (or last available sampling time point before relapse) in all individual patients from the cohort shown in Fig. 1b. Relative mutation frequencies (number of MEN1-mutant / WT droplets) are labeled in white. Mutations which were detected in > 2 droplets were considered. e) Longitudinal kinetics of MEN1 mutant selection in two selected patients from the cohort shown in Fig. 1b. Mutant allele frequencies at different time points during revumenib treatment were analyzed by ddPCR.
